trending Market Intelligence /marketintelligence/en/news-insights/trending/Z2Z7YjLE34LkhJ9PL8bAaA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Gelesis secures $84M to commercialize weight management drug Plenity

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Gelesis secures $84M to commercialize weight management drug Plenity

Gelesis Inc. secured over $84 million by selling shares worth $63.4 million and receiving $21.2 million in grants and loans.

Private equity firm Vitruvian Partners LLP was the largest investor in the equity trade.

Gelesis intends to use the capital secured to commercialize its FDA-approved weight management drug Plenity, which works by absorbing water in the stomach and mixing it with food to make a meal feel more filling.

Gelesis has obtained nearly $100 million this year to support the U.S. launch of Plenity, the company said in a statement.